Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.34 |
| ▸ | ITGAL | P20701 | 9/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365304 | 0.89 | KARS1 (0.39) | SCN10AKARS1OPRD1MAP3K12 | |
| SCHEMBL19706101 | 0.88 | SCN10A (0.35) | SCN10AHDAC10HDAC6ITGB2ICAM1 | |
| SCHEMBL19670247 | 0.80 | PTGS1 (0.39) | KCNH2 | |
| SCHEMBL19670445 | 0.77 | GRM5 (0.39) | — | |
| SCHEMBL19706193 | 0.77 | CNR2 (0.40) | — | |
| SCHEMBL16776128 | 0.75 | FGFR4 (0.38) | SCN10AITGB2ICAM1ITGALKARS1 | |
| SCHEMBL16238200 | 0.75 | SCD (0.37) | SCN10AITGB2ICAM1ITGALKARS1 | |
| SCHEMBL19365428 | 0.75 | HDAC2 (0.48) | — | |
| SCHEMBL19670311 | 0.75 | FGFR4 (0.37) | SCN10AITGB2ICAM1ITGALKARS1 | |
| SCHEMBL19670490 | 0.74 | SLC34A1 (0.36) | SCN10AITGB2ICAM1ITGALKARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SCN10A 3878/4885HDAC10 273/4885HDAC6 25/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | SCN10A 3878/4885HDAC10 273/4885HDAC6 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.